Smith & Nephew’s (SN) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their hold rating on shares of Smith & Nephew (LON:SN – Free Report) in a research note issued to investors on Tuesday morning,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,250 target price on the stock.

A number of other research firms have also recently commented on SN. Citigroup cut Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Berenberg Bank reduced their price target on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a research note on Friday, August 14th. JPMorgan Chase & Co. lowered their price objective on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Jefferies Financial Group restated a “buy” rating and issued a GBX 1,500 target price on shares of Smith & Nephew in a research report on Friday, September 4th. Finally, Shore Capital Group reiterated a “buy” rating and set a GBX 1,000 price target on shares of Smith & Nephew in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Smith & Nephew currently has an average rating of “Hold” and a consensus price target of GBX 1,293.33.

Get Smith & Nephew alerts:

Get Our Latest Report on SN

Smith & Nephew Trading Up 0.4%

Shares of Smith & Nephew stock opened at GBX 1,042 on Tuesday. The stock’s fifty day moving average price is GBX 1,100.61 and its 200 day moving average price is GBX 1,149.25. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The company has a market cap of £11.42 billion, a P/E ratio of 37.52, a PEG ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Read More

• Five stocks we like better than Smith & Nephew
• Aeluma’s Selloff Could Be Setting Up Its Next Big Move
• Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
• The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
• The Fed’s Rate Hike Could Backfire If Oil Prices Collapse

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.